Figure 3.

Only T_N have the potential to express CD117, and the phenomenon can occur in vivo. (A) CBMC and PBMC were activated and the percentage of CD8⁺ T cells expressing CD117 was recorded at the indicated time points. Data are from three independent samples. (B) Purified CCR7⁺/CD45RA⁺ CD8⁺ T_N and CD45RA⁻ CD8⁺ T_CM/EM from PB of adult donors were activated and CD117 expression recorded at the indicated time points. Data are from three independent samples. (C) Expression of CD117 was measured in PB CD8⁺ T cells from six patients with AIM and from six healthy donors (HDs). (D) Expression of CD117 and CD38 was measured in PB CD8⁺ T cells from three patients with AIM and from three HDs. Single representative experiment. (E) PBMC from three patients with AIM, different from those in (D) and all expressing HLA A2, and from three EBV-negative HD were stained with YVL (upper panel) and GLC (lower panel) tetramers. The expression of CD117 is shown in CD8⁺ T cells from an HD and in either tetramer-positive or tetramer-negative CD8⁺ T cells from an AIM patient. Single representative experiment. (F) PBMC from three EBV seropositive HDs expressing the appropriate HLA alleles were stained with tetramers specific for the HLA A2-restricted CLG, GLC, and YVL peptides (left panel) or for the HLA B8-restricted FLR and RAK peptides (right panel). The expression of CD117 is shown in CD8⁺ T cells from tetramer-positive and tetramer-negative CD8⁺ T cells. Single representative experiments.